{"id":"NCT02770625","sponsor":"ISU Abxis Co., Ltd.","briefTitle":"Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease","officialTitle":"A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-03","completion":"2014-08","firstPosted":"2016-05-12","resultsPosted":"2017-07-12","lastUpdate":"2017-07-12"},"enrollment":8,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease, Type 1"],"interventions":[{"type":"DRUG","name":"ISU302","otherNames":["Imiglucerase"]}],"arms":[{"label":"ISU302","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease.","primaryOutcome":{"measure":"The Difference in Hemoglobin Concentration [g/dL]","timeFrame":"from baseline to Week 24","effectByArm":[{"arm":"ISU302","deltaMin":9.49,"sd":0.857}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":8},"commonTop":[]}}